Breno Bittencourt de Brito

Dr. Breno Bittencourt de Brito

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2019 in World Journal of Gastroenterology
Verified
Journal Article
Open access
BBBreno Bittencourt de Brito
Breno Bittencourt de Brito
FSFilipe Antônio França da Silva
Filipe Antônio França da Silva
ASAline Silva Soares
Aline Silva Soares
VPVinícius Afonso Pereira
Vinícius Afonso Pereira
MSMaria Luísa Cordeiro Santos
Maria Luísa Cordeiro Santos
FMFabrício De melo
Fabrício De melo
Helicobacter pylori (H. pylori) is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide. However, its prevalence varies among different geographic areas, and is influenced by several factors. The infection can be acquired by means of oral-oral or fecal-oral transmission, and the pathogen possesses various mechanisms that improve its capacity of mobility, adherence and manipulation of the gastric microenvironment, making possible the colonization of an organ with a highly acidic lumen. In addition, H. pylori presents a large variety of virulence factors that improve its pathogenicity, of which we highlight cytotoxin associated antigen A, vacuolating cytotoxin, duodenal ulcer promoting gene A protein, outer inflammatory protein and gamma-glutamyl transpeptidase. The host immune system, mainly by means of a Th1-polarized response, also plays a crucial role in the infection course. Although most H. pylori-positive individuals remain asymptomatic, the infection predisposes the development of various clinical conditions as peptic ulcers, gastric adenocarcinomas and mucosa-associated lymphoid tissue lymphomas. Invasive and non-invasive diagnostic methods, each of them with their related advantages and limitations, have been applied in H. pylori detection. Moreover, bacterial resistance to antimicrobial therapy is a major challenge in the treatment of this infection, and new therapy alternatives are being tested to improve H. pylori eradication. Last but not least, the development of effective vaccines against H. pylori infection have been the aim of several research studies.

28 July 2020 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MSMaria Luísa Cordeiro Santos
Maria Luísa Cordeiro Santos
BBBreno Bittencourt de Brito
Breno Bittencourt de Brito
FSFilipe Antônio França da Silva
Filipe Antônio França da Silva
MSMariana Miranda Sampaio
Mariana Miranda Sampaio
HMHanna Santos Marques
Hanna Santos Marques
FMFabrício De melo
Fabrício De melo
Helicobacter pylori infection: Beyond gastric manifestations

24 April 2020 in World Journal of Clinical Oncology
Verified
Journal Article
Open access
MSMaria Luísa Cordeiro Santos
Maria Luísa Cordeiro Santos
BBBreno Bittencourt de Brito
Breno Bittencourt de Brito
FSFilipe Antônio França da Silva
Filipe Antônio França da Silva
ABAnelise Costa dos Santos Botelho
Anelise Costa dos Santos Botelho
FMFabrício De melo
Fabrício De melo
Nephrotoxicity in cancer treatment: An overview

30 June 2021 in Expert Review of Vaccines
Verified
Journal Article
Closed access
IVIrineu Dos Santos Viana
Irineu Dos Santos Viana
MSMaria Luísa Cordeiro Santos
Maria Luísa Cordeiro Santos
HMHanna Santos Marques
Hanna Santos Marques
VGVinícius Lima de Souza Gonçalves
Vinícius Lima de Souza Gonçalves
BBBreno Bittencourt de Brito
Breno Bittencourt de Brito
FMFabrício De melo
Fabrício De melo
Introduction: The interest of the world scientific community for an effective vaccine against Helicobacter pylori infection arises from its high prevalence and association with many diseases. Moreover, with an immunological response that is not always effective for the eradication of the bacteria and an increasing antibiotic resistance in the treatment of this infection, the search for a vaccine and new therapeutic modalities to control this infection is urgent. Areas covered: We bring an overview of the infection worldwide, discussing its prevalence, increasing resistance to antibiotics used in its therapy, in addition to the response of the immune system to the infection registered so far. Moreover, we address the most used antigens and their respective immunological responses expected or registered up to now. Finally, we address the trials and their partial results in development for such vaccines. Expert opinion: Although several studies for the development of an effective vaccine against this pathogen are taking place, many are still in the preclinical phase or even without updated information. In this sense, taking into account the high prevalence and association with important comorbidities, the interest of the pharmaceutical industry in developing an effective vaccine against this pathogen is questioned.

1 September 2020 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
RPRute Lopes Pontes
Rute Lopes Pontes
BBBreno Bittencourt de Brito
Breno Bittencourt de Brito
FSFilipe Antônio França da Silva
Filipe Antônio França da Silva
MFMillena Santos Figueredo
Millena Santos Figueredo
TCThiago Macêdo Lopes Correia
Thiago Macêdo Lopes Correia
FMFabrício De melo
Fabrício De melo

14 September 2018 in World Journal of Clinical Oncology
Verified
Journal Article
Open access
BBBreno Bittencourt de Brito
Breno Bittencourt de Brito
FSFilipe Antônio França da Silva
Filipe Antônio França da Silva
FMFabrício De melo
Fabrício De melo
Role of polymorphisms in genes that encode cytokines and Helicobacter pylori virulence factors in gastric carcinogenesis